Antimicrobial peptides: Experimental prevention of osteomyelitis
Year: 2007
Type: dissertation
Abstract: The first chapter introduces the main concepts of this manuscript: osteomyelitis (bone infection), bacterial resistance and antimicrobial peptides (AMPs). As part of a solution to the first two problems, AMPs were investigated for the experimental prevention of infection. The first chapter introduces several AMPs which have been investigated in pre-clinical studies. In our experiments hLF1-11 was used, it consists of amino acids one to eleven of human lactoferrin. We investigated a biodegradable carrier-system for local treatment or prevention of bone infection. The properties of several biodegradable carriers were investigated in chapters two and three. The chapters show the release profiles of hLF1- 11 and gentamicin, a conventional antibiotic, from a dozen different carrier materials. The activity on bacterial strains was confirmed after the release process. Chapter four describes the toxic properties and antimicrobial spectrum of hLF1-11 and control peptides. No specific toxicity was observed on blood and bone cells. The peptide rapidly killed all clinically problematic bacterial strains. These results encouraged us to set up several animal experiments. For these experiments a combination of biodegradable cement (Bonesource) and hLF1-11 was selected. In the rabbit experiments, the release of hLF1-11 from calcium phosphate cement was used as a prophylactic agent against infection with Staphylococcus aureus, the principal cause of osteomyelitis. Chapter five describes the release of hLF1-11 from cement into bone, the AMP rapidly dissipated from the carrier. This was comparable to the earlier in vitro experiments (chapters two and three). Chapter six combines all results from earlier chapters in a prevention study. The rabbits were surgically contaminated with S. aureus and injected with cement and hLF1-11. After removal and culture of the bones, a significant reduction of infection was measured by both hLF1-11 and (standard) gentamicin. This confirms the clinical potential in local treatment of infection. Study aims - To develop a biodegradable carrier for release of hLF1-11. - To evaluate the cytotoxicity and antimicrobial efficacy of hLF1-11. - To compare the results to gentamicin and other antimicrobial peptides for reference. - To implant the carrier and the peptide in an animal model and study its release end efficacy.
Author: Hein P. Stallmann
Institution: Vrije Universiteit Amsterdam
Language: English
Subfield: Microbiology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W1592355481
